Long - term survival in a <font color="blue">phase_1</font> <font color="blue">III_1</font> <font color="blue">,_1</font> <font color="blue">randomised_1</font> <font color="blue">study_1</font> <font color="blue">of_1</font> <font color="blue">topotecan_1</font> <font color="blue">versus_1</font> <font color="blue">paclitaxel_1</font> <font color="blue">in_1</font> <font color="blue">advanced_3</font> <font color="blue">epithelial_3</font> <font color="blue">ovarian_3</font> <font color="blue">carcinoma_3</font> <font color="blue">._3</font> 
<br>
<br> BACKGROUND We have continued to monitor the <font color="blue">survival_1</font> <font color="blue">of_1</font> <font color="blue">patients_3</font> <font color="blue">randomised_2</font> <font color="blue">in_2</font> <font color="blue">a_2</font> <font color="blue">previously_2</font> <font color="blue">reported_2</font> <font color="blue">multicentre_2</font> <font color="blue">phase_2</font> <font color="blue">III_2</font> <font color="blue">study_2</font> <font color="blue">of_2</font> <font color="blue">topotecan_2</font> <font color="blue">versus_2</font> <font color="blue">paclitaxel_3</font> <font color="blue">in_3</font> <font color="blue">patients_5</font> <font color="blue">with_4</font> <font color="blue">advanced_4</font> <font color="blue">epithelial_4</font> <font color="blue">ovarian_4</font> <font color="blue">cancer_4</font> <font color="blue">who_4</font> <font color="blue">had_4</font> <font color="blue">failed_4</font> <font color="blue">one_4</font> <font color="blue">prior_4</font> <font color="blue">platinum_4</font> <font color="blue">-_4</font> <font color="blue">based_4</font> <font color="blue">regimen_4</font> <font color="blue">._4</font> 
<br> PATIENTS AND METHODS <font color="blue">Patients_6</font> <font color="blue">with_6</font> <font color="blue">bidimensionally_6</font> <font color="blue">measurable_6</font> <font color="blue">disease_6</font> <font color="blue">were_2</font> <font color="blue">randomised_2</font> <font color="blue">to_1</font> <font color="blue">topotecan_1</font> ( 1.5 mg / m(2)/day for 5 days ) or paclitaxel ( 175 mg / m(2)/day as a 3-h infusion ) every 21 days . <font color="blue">Patients_1</font> <font color="blue">were_1</font> <font color="blue">eligible_1</font> for treatment with the alternate therapy at third line . The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC <font color="blue">QOL)-C30_1</font> <font color="blue">questionnaire_1</font> <font color="blue">was_1</font> <font color="blue">also_1</font> <font color="blue">used_1</font> <font color="blue">to_1</font> <font color="blue">measure_1</font> <font color="blue">eight_1</font> <font color="blue">symptoms_1</font> <font color="blue">at_1</font> <font color="blue">baseline_1</font> <font color="blue">and_1</font> <font color="blue">during_1</font> <font color="blue">each_1</font> <font color="blue">course_1</font> <font color="blue">(_1</font> <font color="blue">pain_1</font> <font color="blue">,_1</font> <font color="blue">anorexia_1</font> <font color="blue">,_1</font> <font color="blue">diarrhoea_1</font> <font color="blue">,_1</font> <font color="blue">fatigue_1</font> <font color="blue">,_1</font> <font color="blue">nausea_1</font> <font color="blue">and_1</font> <font color="blue">vomiting_1</font> <font color="blue">,_1</font> <font color="blue">dyspnea_1</font> <font color="blue">,_1</font> <font color="blue">constipation_1</font> <font color="blue">and_1</font> <font color="blue">insomnia_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> 
<br> RESULTS <font color="blue">A_3</font> <font color="blue">total_3</font> <font color="blue">of_3</font> <font color="blue">226_7</font> <font color="blue">patients_7</font> <font color="blue">were_1</font> <font color="blue">evaluable_1</font> <font color="blue">for_1</font> <font color="blue">response_1</font> <font color="blue">._1</font> Demographic characteristics were similar in both treatment groups , as were results of the EORTC QOL-30 questionnaire . For the <font color="blue">topotecan_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> median time to progression was 18.9 weeks ( range < 1 to 92.6 + weeks ; 25% censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3 + weeks ; 12.3% censored ) ; P = 0.076 . At 4 years post - randomisation , median survival in the topotecan group was 63.0 weeks ( range < 1 to 238.4 + weeks ; 20.5% censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3 + weeks ; 12.3% censored ) ; P = 0.44 . 
<br> CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non - cumulative haematological toxicity . <font color="blue">Non_1</font> <font color="blue">-_1</font> <font color="blue">haematological_1</font> <font color="blue">toxicity_1</font> <font color="blue">was_1</font> <font color="blue">generally_1</font> <font color="blue">mild_1</font> <font color="blue">for_1</font> <font color="blue">both_1</font> <font color="blue">groups_1</font> <font color="blue">._1</font> The long - term survival rate indicates substantial therapeutic benefit for <font color="blue">this_1</font> <font color="blue">group_2</font> <font color="blue">of_2</font> <font color="blue">patients_2</font> <font color="blue">receiving_2</font> <font color="blue">topotecan_2</font> <font color="blue">at_1</font> <font color="blue">relapse_2</font> <font color="blue">of_2</font> <font color="blue">ovarian_2</font> <font color="blue">cancer_2</font> <font color="blue">._2</font> <font color="blue">
<br>
<br>_1</font>